Vaxart (VXRT) Declines 36% Following Data from Phase 1 Clinical Trial Evaluating Oral COVID-19 Tablet Vaccine Candidate
Tweet
Share
E-mailGet Alerts VXRT Hot Sheet
Up)Join SI Premium – FREE
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Vaxart (NASDAQ: VXRT) Declines 36% Following Data from Phase 1 Clinical Trial Evaluating Oral COVID-19 Tablet Vaccine Candidate
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coinbase (COIN) options to start trading April 20
- PetIQ, Inc. (PETQ) Gains on Barron's Pump
- Manchester United (MANU) Up 9% on Plans to Join a New European Super League, a New Competition Format Funded by JP Morgan
Create E-mail Alert Related Categories
Hot FDA News, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
